• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Akebia Therapeutics

edit

Akebia Therapeutics, Inc., a pharmaceutical company, focuses on treatments for ischemia and improvement of vascular disease. It engages in the clinical development of compounds for the treatment of anemia and ischemia-related disorders. The company offers Omacor for hypertriglyceridemia; and Actonel for osteoporosis. Its products include prolyl hydroxylase enzyme and phosphatase enzyme. Akebia Therapeutics, Inc. was founded in 2007 and is based in Cincinnati, Ohio.

Recent Milestones

edit

• 
  Akebia Therapeutics received $4.1M in Series B funding. (1/9/12)
  Posted 1/9/12 at 7:18pm via finsmes.com
• 
  Akebia Therapeutics received $22M in Series B funding. (4/26/11)
  Posted 4/26/11 at 5:12pm via akebia.com
• 
  Akebia Therapeutics received $16M in Series A funding. (9/15/09)
  Posted 9/18/09 at 5:15am via onbiovc.com

Videos

Screenshots

edit

Sources

1. Akebia Therapeutics, Inc.: Series A $16M (onbiovc.com) [edit]
2. AKEBIA COMPLETES $22M SERIES B FINANCING (akebia.com) [edit]
3. Akebia Therapeutics Raises $4.1M in Series B Financing (finsmes.com) [edit]